Dr. Belani on Impact of Nivolumab's Approval in NSCLC

Chandra P. Belani, MD
Published: Friday, Mar 04, 2016



Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, deputy director, Penn State Hershey Cancer Institute, discusses how the FDA approval of nivolumab (Opdivo) has impacted the treatment paradigm of non–small cell lung cancer (NSCLC).

Nivolumab is approved in NSCLC for patients with both squamous and nonsquamous histologies, Belani explains. The basis of the approval for squamous patients is on data from the phase III CheckMate-057 study, which demonstrated a 3.6-month overall survival benefit with nivolumab versus docetaxel, regardless of staining for PD-1 expression.

In the nonsquamous population, a 2.8-month improvement was demonstrated, Belani adds. Nivolumab can be administered to all nonsquamous patients with NSCLC, an indication that it was approved for in October 2015, in the second-line setting after failure on chemotherapy.



Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, deputy director, Penn State Hershey Cancer Institute, discusses how the FDA approval of nivolumab (Opdivo) has impacted the treatment paradigm of non–small cell lung cancer (NSCLC).

Nivolumab is approved in NSCLC for patients with both squamous and nonsquamous histologies, Belani explains. The basis of the approval for squamous patients is on data from the phase III CheckMate-057 study, which demonstrated a 3.6-month overall survival benefit with nivolumab versus docetaxel, regardless of staining for PD-1 expression.

In the nonsquamous population, a 2.8-month improvement was demonstrated, Belani adds. Nivolumab can be administered to all nonsquamous patients with NSCLC, an indication that it was approved for in October 2015, in the second-line setting after failure on chemotherapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x